RSI-MRI+
Overview
RSI-MRI+ is an FDA-cleared artificial intelligence (AI) powered imaging software developed by HealthLytix (which merged with CorTechs Labs in June 2020). It utilizes an advanced diffusion MRI technique called Restriction Spectrum Imaging (RSI), biophysical models, and AI to enhance the visibility of restricted water, a key indicator of cancerous tissue, particularly for prostate cancer. The software is designed to assist radiologists, urologists, and other clinicians in the analysis and interpretation of medical images by providing improved visualization and quantification of restricted water compared to standard diffusion-weighted imaging (DWI). RSI-MRI+ automatically segments the prostate on anatomical T2-weighted images using deep learning algorithms and fuses the derived Restricted Signal Map with anatomical images to support precise anatomical localization. It also generates automated reports, including total prostate volume and segmented prostate images.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Restricted Signal Map for enhanced visualization of restricted diffusion
- Color Fusion Series to overlay restricted signal onto anatomical images
- Automated Prostate Segmentation using deep learning algorithms
- Automated Segmentation Report with prostate volume and segmented images
- DICOM export for compatibility with PACS workstations
- Utilizes Restriction Spectrum Imaging (RSI) technique
- AI-powered analysis of diffusion-weighted MRI data
Use Cases
- Early detection of prostate cancer
- Improved diagnosis of prostate cancer
- Enhanced visualization and quantification of restricted water in cancerous tissue
- Assisting radiologists and urologists in analyzing prostate MRI data
- Post-acquisition image processing for MRI scans
What Physicians Need to Know
OnQ Prostate (formerly RSI-MRI+) leverages Restriction Spectrum Imaging (RSI) to provide enhanced visualization and quantification of prostate tissue, which can aid in distinguishing aggressive cancer cells from benign tissue. This can be particularly useful in cases where standard MRI findings are ambiguous or when a patient has persistently rising PSA with negative prior biopsies. The quantitative maps and automated segmentations can improve confidence in diagnosis, assist in biopsy targeting, and facilitate communication with urologists and other specialists. Remember to integrate the quantitative RSI metrics and regions of interest into your diagnostic impression for comprehensive reporting, especially when billing with relevant CPT codes.
Cortechs.ai solutions are designed for integration into existing clinical workflows, with options for secure data transfer via TLS v1.2 connections and automated DICOM proxy (CTXNode) for efficient image upload and result delivery. Partnerships with enterprise AI ecosystems like CARPL.ai further expand accessibility and integration possibilities within larger healthcare IT infrastructures.
Details
| Category | Oncology AI |
| Pricing | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Unknown |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Radiology, Urology |
Support & Reliability
What the Web Says
RSI-MRI+ by Cortechs.ai is an FDA-cleared advanced imaging software designed to improve prostate cancer detection and diagnosis. It utilizes Restriction Spectrum Imaging (RSI), a patented diffusion MRI technique, to enhance the visualization and quantification of restricted water compared to standard DWI. Physicians have expressed positive opinions, noting its potential to improve accuracy and reproducibility in prostate MRI, reduce unnecessary biopsies, and aid in earlier detection of clinically significant prostate cancer.
Overall: PositiveStrengths
- Improves prostate cancer detection and diagnosis.
- Enhances visualization and quantification of restricted water compared to standard DWI.
- Potential to improve accuracy and reproducibility of prostate MRI.
- May lead to fewer unnecessary biopsies and greater diagnostic yield.
- Aids in earlier detection of clinically significant prostate cancer.
- Provides increased conspicuity of restricted diffusion.
Limitations
No significant limitations found in public reviews. Consider checking vendor documentation or requesting a demo for a thorough evaluation.
Based on reviews from: Capterra, cortechs.ai, YouTube, G2, physicianaitools.com, appliedradiology.com, Reddit
Last updated: 2026-10-31
Ratings & Reviews
No reviews yet. Be the first to review this tool!
